Alina Aguilar-Gonzalez, Karlitha Leonard, & Dr. Ahmed Awad
Detecting Pancreatic Ductal Adenocarcinoma in its early stages poses a significant challenge, while treating it effectively remains difficult due to chemoresistance and the inability to operate on metastases. Although current chemotherapy agents can shrink tumors and deter reoccurrence, the one-year survival rate stands at a mere eighteen percent. Gemcitabine, the standard FDA-approved chemotherapy for cancers like PDAC, targets ribonucleotide reductase (RNR). However, controversies surround Gemcitabine, including cytotoxicity, poor cellular penetration, and high rates of chemoresistance.
Ribonucleotide reductase (RNR) is a critical enzyme catalyzing the conversion of ribonucleotides to deoxyribonucleotides, vital for DNA synthesis and repair. By inhibiting RNR, which plays a pivotal role in de novo deoxynucleotide triphosphate (dNTP) synthesis, tumor cell growth can be impeded as cancer cells heavily rely on DNA synthesis for replication.
In this study, we synthesized four aryl sulfonamide nucleoside analogues resembling Gemcitabine, each modified at the C-2’ region with benzene sulfonamide derivatives featuring electron-withdrawing groups like fluorine and chlorine. These modifications were hypothesized to enhance binding affinity towards RNR. Computational analyses were conducted on these compounds to assess their interactions with the large M1 subunit of Ribonucleotide Reductase (HRMM1), including amino acid residues, hydrophobic/hydrophilic interactions, and RMSD values.
Biological activity and drug-likeness of the aryl sulfonamide compounds were evaluated through PASS and SwissADMET analysis, identifying three top compounds: 2-chloro-4-fluoro-5-sulfamoylbenzoic acid (Compound A), 4-fluorobenzoic acid (Compound B), and 3-fluoro-4(trifluoromethyl)phenylacetic acid (Compound C). PASS prediction analysis indicated a higher Pa value compared to Pi value for each compound, suggesting a greater likelihood of biological activity. Compounds A, B, and C yielded Pa > Pi values of 0.198 > 0.011, 0.107 > 0.029, and 0.078 > 0.051, respectively. Compounds A, B, and C also demonstrated binding affinities to the active site of RNR, with average Edoc scores of -27.65, -27.54, and -29.28 kJ/mol, respectively. The promising results from molecular docking, pharmacological profile analysis, and biological activity suggest that these aryl compounds are potential RNR inhibitors for pancreatic cancer.
